We scan new podcasts and send you the top 5 insights daily.
Matias expects classic psychedelics may reach approval first, but says best-in-class compounds may be non-hallucinogenic. He cites Gilgamesh's AbbVie-linked program and Delix's positive Phase 1b data as evidence for this newer generation. The thesis is that first-in-class does not stay best-in-class by default, and he is bullish on the category.
Major pharma investment, like Lilly's $2.8B deal, is seen as a 'rising tide' that lifts all companies in the psychedelic space. Progress in one area (e.g., DMT) builds momentum for others (e.g., psilocybin, LSD), creating a collaborative effect where individual company advancements benefit the entire industry's legitimacy and growth.
Recent acquisitions, such as Eli Lilly buying Atai and AbbVie buying Gigamesh, are the clearest signal that psychedelic therapies are no longer a niche R&D area. Major pharmaceutical companies now view the space as a core part of their growth strategy and a substantial business opportunity.
SciMed chose to accept more market and regulatory risk in psychedelics because the clinical science looked strong, Matias says. He points to uncertainty over payer reimbursement and pharma acquisitions as the tradeoff for underwriting less technical risk. The FDA's openness, including breakthrough designations, made that bet feel more reasonable.
Eli Lilly, one of pharma's most powerful brands, acquiring psychedelics company Atai Beckley is a major validation for the entire sector. This move signals that previously controversial therapeutic areas are now open for M&A by top-tier, conservative pharma companies, potentially opening the floodgates for more deals.
While Compass's psilocybin shows strong Phase 3 data, its 6-8 hour in-office administration is a major commercial hurdle compared to J&J's Spravato (2 hours). The key investment thesis is that its significantly longer-lasting effect will justify the logistical complexity for patients, providers, and payers.
Eli Lilly acquired Atai Beckley, whose lead drug offers a more intense psychedelic experience but a much shorter duration than competitors like psilocybin. This highlights a key business calculation: reduced clinic time and monitoring costs can outweigh the risks of a more potent drug.
The public perception of a downturn in the psychedelic space, fueled by falling company valuations and a key FDA rejection, is misleading. Behind the scenes, the rate and quality of scientific publications and clinical trials are higher than ever, suggesting the underlying research is robust and accelerating.
The future market for psychedelic therapies will not be monolithic. Companies are developing drugs that cater to different patient desires, such as the length of the clinical session (a few hours vs. six) and the intensity of the hallucinogenic experience (from a full 'trip' to avoiding it entirely), creating distinct market segments.
The long duration (4-6+ hours) of first-generation psychedelics like psilocybin creates a major commercial bottleneck for clinics. Atai's focus on shorter, two-hour compounds is a strategic bet on scalability, allowing clinics to treat more patients per day and reducing the exhaustion of monitoring staff.
Current mental health drugs force a choice: slow-acting daily pills or rapid-acting treatments like Spravato that require frequent, life-disrupting clinic visits. Psychedelic therapies offer a new paradigm by combining rapid onset of efficacy with durability lasting weeks or months from a single dose.